Population structure and HLA DRB1*1501 in the response of subjects with multiple sclerosis to first-line treatments

作者：Gross Robert; Healy Brian C; Cepok Sabine; Chitnis Tanuja; Khoury Samia J; Hemmer Bernard; Weiner Howard L; Hafler David A; De Jager Philip L^*

来源：Journal of Neuroimmunology, 2011, 233(1-2): 168-174.

DOI：10.1016/j.jneuroim.2010.10.038

• Multiple sclerosis
• Disease modifying treatment
• Genetic

Using retrospectively collected outcome data for treatment naive subjects treated with either glatiramer acetate (GA) (n=332) or interferon beta (IFN beta) (n=424), we replicated the lack of a significant difference in efficacy between? these treatments. Further, for both treatments, we observed a decline in the hazard of a relapse over time, which may suggest the existence of subsets of subjects with differential responses to each treatment. The HLA DRB1*1501 allele explained some of this variation in event-free survival while on GA, and we found suggestive evidence that an IRF8 polymorphism influences event-free survival in IFN beta treated subjects.

• 出版日期2011-4